nuwiq 2,000unit powder and solvent for solution for injection vials
octapharma ltd - simoctocog alfa - powder and solvent for solution for injection - 2000unit
nuwiq 500unit powder and solvent for solution for injection vials
octapharma ltd - simoctocog alfa - powder and solvent for solution for injection - 500unit
octaplex powder and solvent for solution for infusion
octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor ii, human blood coagulation factor vii, human blood coagulation factor ix, human blood coagulation factor x, protein c, protein s - powder and solvent for solution for infusion - 14-38iu/ml+ 9-24iu/ml+ 25iu/ml+ 18-30iu/ml+ 13-31iu/ml+ 12-32iu/ml
albumin human 20%
octapharma limited - human albumin - solution for injection - 20 %w/v
albumin human 20%
octapharma limited - human albumin - 20 millilitre
rhesonativ pdr+solv for soln for inj 1250 iu international unit
octapharma limited - anti-d immunoglobulin - pdr+solv for soln for inj - 1250 iu international unit
gammanorm
octapharma australia pty ltd - immunoglobulin - normal -
octagam 10%
octapharma australia pty ltd - immunoglobulin g - human; human normal immunoglobulin -
intravenous start kit
octapharma australia pty ltd - 33963 - intravenous start kit - a packaged collection of equipment that includes needles and tubing that is used to establish intravenous (iv) access for the administration of intravenous solutions.
rhesonativ
octapharma new zealand ltd - anti-d [rho] immunoglobulin 625 iu/ml; plasma protein fraction 165 mg/ml (human) - solution for injection - 1250 iu - active: anti-d [rho] immunoglobulin 625 iu/ml plasma protein fraction 165 mg/ml (human) excipient: glycine immunoglobulin a. not less than or equal to.05% of total protein polysorbate 80 sodium tributyl phosphate water for injection - · prevention of rh(d) immunisation in rh(d) negative women. - pregnancy/delivery of a rh-positive baby. - abortion/threatened abortion, ectopic pregnancy or hydatidiform mole. - transplacental haemorrhage (tph) resulting from ante-partum haemorrhage (aph), amniocentesis, chorionic biopsy or obstetric manipulative procedures, e.g. external version, or abdominal trauma. · treatment of rh(d) negative persons after incompatible transfusions of rh(d) positive blood or other products containing red blood cells.